Picture EBD Group Biotech Showcase 2024 San Francisco 650x100px

Document › Details

Agilent Technologies Inc.. (3/2/17). "Press Release: Agilent Technologies Introduces Postnatal Assay for Detection of Genetic Anomalies. GenetiSure Dx Postnatal Assay Can Help Move Inquiries from Cause to Care Faster". Santa Clara, CA.

	Region	EU (European Union)
	Organisation	Agilent Technologies Inc. (NYSE: A)
	Product	GenetiSure Dx Postnatal CGH Assay
	Person	Verrelst, Herman (Biocartis 202304– Board Chair before CEO before Agilent + Cartagenia + Medicim + Data4s)
	Person 2	Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)

Agilent Technologies Inc. (NYSE: A) has introduced its first comparative genomic hybridization (CGH) assay for diagnostic use: the GenetiSure Dx Postnatal Assay. This assay will enable clinical geneticists to detect genetic anomalies earlier and more accurately than traditional methods can.

Such anomalies have been associated with developmental delay, intellectual disability, autism, congenital irregularities and dysmorphic features in children and adults.

The GenetiSure Dx Postnatal Assay is the result of an extensive clinical validation and brings CGH technology into diagnostics. This assay is based on Agilent's proprietary array for comparative genomic hybridization providing data on copy number variations and absence of heterozygosity, and will carry CE Marking for in vitro diagnostics.

By helping to identify a definitive genetic diagnosis, the assay can rapidly change the focus of a medical investigation from finding the cause to administering appropriate medical care and family support.

"The GenetiSure Dx Postnatal Assay has been developed for cytogenetic laboratories, combining high-quality data with easy laboratory setup and streamlined protocols," said Herman Verrelst, Agilent vice president and general manager of the company's Genomics Solutions Division and Clinical Applications Division. "From DNA to data analysis, this assay allows for easy implementation into the clinical routine."

Verrelst noted that GenetiSure Dx is a validated solution that will help clinical labs implement important cytogenetic testing.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Victoria Wadsworth-Hansen
Agilent Technologies
+1 408-553-2005
+45 29336980
victoria.wadsworth-hansen@agilent.com

Record changed: 2023-06-05